TaiMed Biologics (4147) - Total Assets
Based on the latest financial reports, TaiMed Biologics (4147) holds total assets worth NT$4.81 Billion TWD (≈ $151.56 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore TaiMed Biologics cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
TaiMed Biologics - Total Assets Trend (2009–2025)
This chart illustrates how TaiMed Biologics's total assets have evolved over time, based on quarterly financial data. See TaiMed Biologics (4147) net assets for net asset value and shareholders' equity analysis.
TaiMed Biologics - Asset Composition Analysis
Current Asset Composition (December 2025)
TaiMed Biologics's total assets of NT$4.81 Billion consist of 69.1% current assets and 30.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 18.7% |
| Accounts Receivable | NT$64.65 Million | 1.3% |
| Inventory | NT$827.73 Million | 17.2% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$442.15 Million | 9.2% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how TaiMed Biologics's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see TaiMed Biologics market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TaiMed Biologics's current assets represent 69.1% of total assets in 2025, an increase from 0.0% in 2009.
- Cash Position: Cash and equivalents constituted 18.7% of total assets in 2025, down from 43.8% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, a decrease from 36.0% in 2009.
- Asset Diversification: The largest asset category is inventory at 17.2% of total assets.
TaiMed Biologics Competitors by Total Assets
Key competitors of TaiMed Biologics based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $553.60 Million |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $260.53 Million |
TaiMed Biologics - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.11 | 25.18 | 9.54 |
| Quick Ratio | 9.84 | 17.78 | 4.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$3.07 Billion | NT$3.26 Billion | NT$2.28 Billion |
TaiMed Biologics - Advanced Valuation Insights
This section examines the relationship between TaiMed Biologics's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.49 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | -3.8% |
| Total Assets | NT$4.81 Billion |
| Market Capitalization | $504.04 Million USD |
Valuation Analysis
Below Book Valuation: The market values TaiMed Biologics's assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: TaiMed Biologics's assets decreased by 3.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for TaiMed Biologics (2009–2025)
The table below shows the annual total assets of TaiMed Biologics from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$4.81 Billion ≈ $151.56 Million |
-3.77% |
| 2024-12-31 | NT$5.00 Billion ≈ $157.50 Million |
+28.39% |
| 2023-12-31 | NT$3.89 Billion ≈ $122.68 Million |
-5.05% |
| 2022-12-31 | NT$4.10 Billion ≈ $129.21 Million |
-11.05% |
| 2021-12-31 | NT$4.61 Billion ≈ $145.26 Million |
-11.27% |
| 2020-12-31 | NT$5.20 Billion ≈ $163.71 Million |
+9.84% |
| 2019-12-31 | NT$4.73 Billion ≈ $149.04 Million |
-1.26% |
| 2018-12-31 | NT$4.79 Billion ≈ $150.94 Million |
+6.40% |
| 2017-12-31 | NT$4.50 Billion ≈ $141.87 Million |
-6.22% |
| 2016-12-31 | NT$4.80 Billion ≈ $151.28 Million |
-2.53% |
| 2015-12-31 | NT$4.93 Billion ≈ $155.21 Million |
+161.95% |
| 2014-12-31 | NT$1.88 Billion ≈ $59.25 Million |
+163.14% |
| 2013-12-31 | NT$714.72 Million ≈ $22.52 Million |
+8.38% |
| 2012-12-31 | NT$659.45 Million ≈ $20.78 Million |
-22.82% |
| 2011-12-31 | NT$854.39 Million ≈ $26.92 Million |
-19.25% |
| 2010-12-31 | NT$1.06 Billion ≈ $33.33 Million |
+71.42% |
| 2009-12-31 | NT$617.22 Million ≈ $19.45 Million |
-- |
About TaiMed Biologics
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinica… Read more